| Identification | Back Directory | [Name]
GSK 2033 | [CAS]
1221277-90-2 | [Synonyms]
GSK 2033
LXR antagonist 2033
GSK2033 >=98% (HPLC)
2,4,6-Trimethyl-N-[[3'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]methyl]-N-[[5-(trifluoromethyl)-2-furanyl]methyl]benzenesulfonamide
Benzenesulfonamide, 2,4,6-trimethyl-N-[[3'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]methyl]-N-[[5-(trifluoromethyl)-2-furanyl]methyl]- | [Molecular Formula]
C29H28F3NO5S2 | [MDL Number]
MFCD28396416 | [MOL File]
1221277-90-2.mol | [Molecular Weight]
591.66 |
| Chemical Properties | Back Directory | [storage temp. ]
2-8°C | [solubility ]
DMF:5.0(Max Conc. mg/mL);8.45(Max Conc. mM)
DMSO:17.46(Max Conc. mg/mL);29.51(Max Conc. mM) | [form ]
powder | [color ]
white to beige |
| Hazard Information | Back Directory | [Uses]
GSK 2033 is a potent LXR antagonist. | [Biochem/physiol Actions]
GSK2033 is an antagonist of the nuclear receptor liver-X-receptor (LXR) with pIC50 values of 7.0 for LXRα and 7.4 for LXRβ. Treatment of murine CD41 T cells with GSK2033 enhanced cellular proliferation and Th1/Th2/Th17 differentiation. In another study, the conjugated linoleic acid (CLA)-induced expression of efflux protein ATP-binding-cassette transporter A1 (ABCA1) was completely abolished by preincubation with GSK2033, showing that CLA mediated regulation of ABCA-1 expression is LXR dependent. | [storage]
Store at +4°C |
|
| Company Name: |
Sigma-Aldrich
|
| Tel: |
021-61415566 800-8193336 |
| Website: |
https://www.sigmaaldrich.cn |
|